Baxter International Inc. (BAX) exhibits 30.1% gross margins and -2.4% return on invested capital within Health Care (Medical/Dental Instruments), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 30.1% gross profitability converts into -2.7% operating margin and -2.4% ROIC, outpacing sector cost of capital.
ROIC: -2.4% // GM: 30.1%YoY revenue trajectory of +5.7% paired with 2.79% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +5.7% // FCF YLD: 2.79%Altman Z-Score of 2.22 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 2.22 // F-SCORE: 6/9Trading at 24.0x trailing P/E (18.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $24.22 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Medical/Dental Instruments require continuous execution to defend -8.5% net margins.
NET MARGIN: -8.5% // D/E: 0.96x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for BAX & activate live FRED threshold breach alerts.